<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04991922</url>
  </required_header>
  <id_info>
    <org_study_id>BG-001</org_study_id>
    <nct_id>NCT04991922</nct_id>
  </id_info>
  <brief_title>BostonGene-Integrated Genomic Registry (BIGR)</brief_title>
  <official_title>BostonGene-Integrated Genomic Registry Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BostonGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BostonGene</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this project is to develop a comprehensive database of genomic,&#xD;
      transcriptomic, molecular, and clinical characteristics of oncology patients to discover,&#xD;
      define, and develop genomic and transcriptomic markers to improve future clinical outcomes&#xD;
      across cancer types&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Immuno- and targeted therapies have shown promising results for many types of cancer (1).&#xD;
      However, the effectiveness of these treatments is not optimal for many patients (2).&#xD;
      Therefore, further research is needed to discover, define, and develop genomic,&#xD;
      transcriptomic, and integrated molecular markers that can improve clinical outcomes across&#xD;
      cancer types (3). Unfortunately, current research is restricted by the limited availability&#xD;
      of genomic and transcriptomic results linked to clinical outcomes (3). This study will allow&#xD;
      for the collection of key clinical data, including longitudinal follow-up, linked with&#xD;
      individual genetic and molecular findings in a single comprehensive registry-based databank.&#xD;
      Analysis of these data may lead to advances across cancer subtypes through the identification&#xD;
      of transcriptomic and genomic associations with therapies.&#xD;
&#xD;
      Clinical and pathological information, including detailed genetic information from a&#xD;
      participant's tumor biopsy, will be obtained by the research staff for each participant&#xD;
      enrolled in the BIGR Study. Clinical information will include relevant details about the&#xD;
      patient's diagnosis and treatment and will be stored in a secure electronic registry&#xD;
      database. No extra scans or procedures for this study will be collected as part of this&#xD;
      study. Information will be collected regarding a participant's initial diagnosis, treatment,&#xD;
      and outcome. To obtain this information, study staff will contact participants or a&#xD;
      participant's doctor at regular time intervals for up to 15 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2036</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2031</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>association between major finding and outcome, Descriptive</measure>
    <time_frame>5 years</time_frame>
    <description>associations between genomic findings and outcomes of cancer patients who have undergone comprehensive sequencing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Predictive probability</measure>
    <time_frame>5 years</time_frame>
    <description>identify molecular findings associated with therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical trials matching</measure>
    <time_frame>5 years</time_frame>
    <description>identify and link registry subjects to future molecular-based clinical research</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100000</enrollment>
  <condition>Malignancy</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects will be identified for the BIGR study from a larger group of patients undergoing&#xD;
        BostonGene clinical testing (e.g., BostonGene Tumor Portrait TestTM).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Suspected or confirmed malignancy&#xD;
&#xD;
          2. Planned comprehensive genomic (&gt; 100 genes) and/or molecular analysis; or genomic&#xD;
             and/or molecular data available from prior sequencing&#xD;
&#xD;
          3. Baseline demographics and treatment information available&#xD;
&#xD;
          4. Willingness for future contact by BIRG study personnel to provide information&#xD;
             regarding associated cancer outcomes and treatment.&#xD;
&#xD;
          5. Signed informed consent to participate in the study.&#xD;
&#xD;
          6. Living in the United States at the time of enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Life expectancy &lt; 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathan Fowler</last_name>
    <role>Principal Investigator</role>
    <affiliation>BostonGene</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nathan Fowler</last_name>
    <phone>+1-617-658-4545</phone>
    <email>nathan.fowler@bostongene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>BostonGene</name>
      <address>
        <city>Waltham</city>
        <state>Massachusetts</state>
        <zip>02453</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krystle Nomie, PhD</last_name>
      <phone>617-658-4545</phone>
      <email>krystle.nomie@bostongene.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Murciano-Goroff YR, Warner AB, Wolchok JD. The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Res. 2020 Jun;30(6):507-519. doi: 10.1038/s41422-020-0337-2. Epub 2020 May 28.</citation>
    <PMID>32467593</PMID>
  </reference>
  <reference>
    <citation>Sambi M, Bagheri L, Szewczuk MR. Current Challenges in Cancer Immunotherapy: Multimodal Approaches to Improve Efficacy and Patient Response Rates. J Oncol. 2019 Feb 28;2019:4508794. doi: 10.1155/2019/4508794. eCollection 2019. Review.</citation>
    <PMID>30941175</PMID>
  </reference>
  <reference>
    <citation>Olivier M, Asmis R, Hawkins GA, Howard TD, Cox LA. The Need for Multi-Omics Biomarker Signatures in Precision Medicine. Int J Mol Sci. 2019 Sep 26;20(19). pii: E4781. doi: 10.3390/ijms20194781. Review.</citation>
    <PMID>31561483</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 28, 2021</study_first_submitted>
  <study_first_submitted_qc>July 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2021</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>precision medicine</keyword>
  <keyword>WES</keyword>
  <keyword>RNA-seq</keyword>
  <keyword>immuno-therapy</keyword>
  <keyword>genomic</keyword>
  <keyword>transcriptomic</keyword>
  <keyword>multiomic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

